58 96

Cited 0 times in

Stratification based on adverse laboratory/pathological features for predicting overall survival in patients undergoing radical prostatectomy: A K-CaP registry-based analysis

 Jee Soo Park  ;  Kyo Chul Koo  ;  In Young Choi  ;  Ji Youl Lee  ;  Jun Hyuk Hong  ;  Choung-Soo Kim  ;  Hyun Moo Lee  ;  Sung Kyu Hong  ;  Seok-Soo Byun  ;  Koon Ho Rha  ;  Byung Ha Chung  ;  Kwang Suk Lee 
 MEDICINE, Vol.98(45) : e17931, 2019 
Journal Title
Issue Date
Biomarkers, Tumor/blood* ; Humans ; Male ; Neoplasm Grading* ; Neoplasm Invasiveness/pathology ; Neoplasm Recurrence, Local/diagnosis ; Neoplasm Recurrence, Local/mortality ; Neoplasm Recurrence, Local/pathology ; Predictive Value of Tests ; Progression-Free Survival ; Prostate-Specific Antigen/blood* ; Prostatectomy/mortality ; Prostatic Neoplasms/mortality ; Prostatic Neoplasms/pathology* ; Prostatic Neoplasms/surgery ; Registries ; Seminal Vesicles/pathology
When making clinical decisions concerning additional treatment for patients who have undergone radical prostatectomy (RP), adverse laboratory/pathological features are considered major factors. We investigated and compared the prognostic efficacy of adverse laboratory/pathological features in predicting overall survival (OS) and biochemical failure (BCF) in these patients.The Korean Prostate Cancer Database was used to identify patients undergoing RP between May 2001 and April 2013. Patients with incomplete clinicopathological data or positive lymphadenectomy results were excluded. Finally, 4486 patients included in the final analysis were categorized based on their adverse laboratory/pathological features.Adverse pathological features and detectable prostate-specific antigen (PSA) levels 6 weeks after surgery were observed in 1977 (44.1%) and 634 (14.1%) patients, respectively. PSA levels, pathological Gleason score ≥8, adverse pathological features [positive surgical margin (PSM), seminal vesicle invasion (SVI), and extracapsular extension (ECE)], and adverse laboratory features (detectable PSA levels after 6 weeks) together were significant predictors of BCF-free survival (BCFFS). SVI was identified as a predictor of OS. Additionally, patients with ECE, PSM, and detectable PSA levels after 6 weeks, but without SVI, showed similar OS to those without ECE, PSM, and detectable PSA levels after 6 weeks and with SVI (log-rank test, P = .976).We successfully stratified patients based on adverse laboratory/pathological features after RP and demonstrated that these are important prognostic factors for OS and BCFFS. Additionally, we identified the criteria for selecting appropriate patients for undergoing additional treatment based on OS and BCFFS.
Files in This Item:
T201904634.pdf Download
Appears in Collections:
1. College of Medicine (의과대학) > Dept. of Urology (비뇨의학교실) > 1. Journal Papers
Yonsei Authors
Koo, Kyo Chul(구교철) ORCID logo https://orcid.org/0000-0001-7303-6256
Rha, Koon Ho(나군호) ORCID logo https://orcid.org/0000-0001-8588-7584
Park, Jee Soo(박지수) ORCID logo https://orcid.org/0000-0001-9976-6599
Lee, Kwang Suk(이광석) ORCID logo https://orcid.org/0000-0002-7961-8393
Chung, Byung Ha(정병하) ORCID logo https://orcid.org/0000-0001-9817-3660
사서에게 알리기


Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.